Umezaki Yojiro, Motomura Haruhiko, Egashira Rui, Toyofuku Akira, Naito Toru
Section of Geriatric Dentistry, Department of General Dentistry, Fukuoka Dental College, Fukuoka.
Department of Psychosomatic Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Clin Neuropharmacol. 2023;46(3):123-125. doi: 10.1097/WNF.0000000000000545. Epub 2023 Mar 10.
Oral cenesthopathy is an uncomfortable and bizarre oral sensation without corresponding organic findings. Although some treatment options, including antidepressants and antipsychotic drugs, have been reported to be effective, the condition remains refractory. Here, we report a case of oral cenesthopathy treated with brexpiprazole, a recently approved D2 partial agonist.
A 57-year-old woman presented with a complained of softened incisors. Furthermore, she could not perform housework because of the discomfort. The patient did not respond to aripiprazole. However, she responded to a combination of mirtazapine and brexpiprazole. The visual analog scale score for the patient's oral discomfort decreased from 90 to 61. The patient's condition improved enough to resume housework.
Brexpiprazole and mirtazapine may be considered for the treatment of oral cenesthopathy. Further investigations are warranted.
口腔感知异常是一种没有相应器质性病变的不适且怪异的口腔感觉。尽管已有报道称包括抗抑郁药和抗精神病药物在内的一些治疗方法有效,但该病症仍然难治。在此,我们报告一例使用最近获批的D2部分激动剂布雷哌唑治疗口腔感知异常的病例。
一名57岁女性主诉门牙变软。此外,由于不适她无法做家务。该患者对阿立哌唑无反应。然而,她对米氮平与布雷哌唑的联合治疗有反应。患者口腔不适的视觉模拟评分从90降至61。患者的病情改善到足以恢复做家务。
布雷哌唑和米氮平可考虑用于治疗口腔感知异常。有必要进行进一步研究。